MX2013006980A - Composition with a proton-pump inhibitor and an h2 antagonist. - Google Patents

Composition with a proton-pump inhibitor and an h2 antagonist.

Info

Publication number
MX2013006980A
MX2013006980A MX2013006980A MX2013006980A MX2013006980A MX 2013006980 A MX2013006980 A MX 2013006980A MX 2013006980 A MX2013006980 A MX 2013006980A MX 2013006980 A MX2013006980 A MX 2013006980A MX 2013006980 A MX2013006980 A MX 2013006980A
Authority
MX
Mexico
Prior art keywords
composition
antagonist
proton
pump inhibitor
pharmaceutically acceptable
Prior art date
Application number
MX2013006980A
Other languages
Spanish (es)
Other versions
MX354999B (en
Inventor
María Angélica Arzola Paniagua
Héctor Senosiain Arroyo
Luis Manuel Acosta González
Original Assignee
Alparis Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alparis Sa De Cv filed Critical Alparis Sa De Cv
Priority to MX2013006980A priority Critical patent/MX354999B/en
Priority to PE2014000677A priority patent/PE20150164A1/en
Priority to DO2014000103A priority patent/DOP2014000103A/en
Priority to CR20140220A priority patent/CR20140220A/en
Priority to CO14101483A priority patent/CO7020186A1/en
Priority to CL2014001255A priority patent/CL2014001255A1/en
Priority to GT201400093A priority patent/GT201400093A/en
Priority to BR102014014857-4A priority patent/BR102014014857A2/en
Publication of MX2013006980A publication Critical patent/MX2013006980A/en
Publication of MX354999B publication Critical patent/MX354999B/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention refers to an oral pharmaceutical composition comprising the combination of a proton-pump inhibitor and an H2 antagonist and the pharmaceutically acceptable salts thereof, additionally including pharmaceutically acceptable excipients or vehicles; as well as a process for the manufacture of a composition and use of the rabeprazole-famotidine or dexrabeprazole-famotidine combination with synergistic therapeutic activity indicated for treating gastroesophageal reflux, night acid reflux, peptic ulcer and/or eradication of H. pylori.
MX2013006980A 2013-06-18 2013-06-18 Composition with a proton-pump inhibitor and an h2 antagonist. MX354999B (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MX2013006980A MX354999B (en) 2013-06-18 2013-06-18 Composition with a proton-pump inhibitor and an h2 antagonist.
PE2014000677A PE20150164A1 (en) 2013-06-18 2014-05-12 COMPOSITION WITH A PROTON PUMP INHIBITOR AND AN H2 ANTAGONIST
DO2014000103A DOP2014000103A (en) 2013-06-18 2014-05-12 COMPOSITION WITH A PROTON PUMP INHIBITOR AND A H2 ANTAGONIST
CR20140220A CR20140220A (en) 2013-06-18 2014-05-12 COMPOSITION WITH A PROTON PUMP INHIBITOR AND A H2 ANTAGONIST
CO14101483A CO7020186A1 (en) 2013-06-18 2014-05-12 Composition with a proton pump inhibitor and an h2 antagonist
CL2014001255A CL2014001255A1 (en) 2013-06-18 2014-05-13 Use of a combination of famotidine-dexrabeprazole or famotidine-rabeprazole for the treatment of gastroesophageal reflux disease (erge), nocturnal acid leakage (ean), peptic ulcer and / or eradication of h. pylori; composition containing a proton pump inhibitor and an h2 antagonist; and its manufacturing process.
GT201400093A GT201400093A (en) 2013-06-18 2014-05-13 COMPOSITION WITH A PROTON PUMP INHIBITOR AND A H2 ANTAGONIST
BR102014014857-4A BR102014014857A2 (en) 2013-06-18 2014-06-17 Composition with a proton pump inhibitor and an h2 antagonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2013006980A MX354999B (en) 2013-06-18 2013-06-18 Composition with a proton-pump inhibitor and an h2 antagonist.

Publications (2)

Publication Number Publication Date
MX2013006980A true MX2013006980A (en) 2014-12-19
MX354999B MX354999B (en) 2018-03-28

Family

ID=51610703

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006980A MX354999B (en) 2013-06-18 2013-06-18 Composition with a proton-pump inhibitor and an h2 antagonist.

Country Status (8)

Country Link
BR (1) BR102014014857A2 (en)
CL (1) CL2014001255A1 (en)
CO (1) CO7020186A1 (en)
CR (1) CR20140220A (en)
DO (1) DOP2014000103A (en)
GT (1) GT201400093A (en)
MX (1) MX354999B (en)
PE (1) PE20150164A1 (en)

Also Published As

Publication number Publication date
GT201400093A (en) 2015-11-16
PE20150164A1 (en) 2015-02-25
CL2014001255A1 (en) 2014-10-10
MX354999B (en) 2018-03-28
CO7020186A1 (en) 2014-08-11
BR102014014857A2 (en) 2015-06-02
DOP2014000103A (en) 2014-12-31
CR20140220A (en) 2014-08-21

Similar Documents

Publication Publication Date Title
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2015016421A (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease.
IN2015DN01156A (en)
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
MX2015016344A (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease.
EA201690223A1 (en) FACTOR INHIBITORS IN THE COMPLEMENT BASED ON PIPERIDININILINDOL DERIVATIVES AND THEIR APPLICATION
MX2015009592A (en) Quinoline and quinazoline amides as modulators of sodium channels.
EA201690287A1 (en) 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY
MX365939B (en) Nuclear transport modulators and uses thereof.
MX2015017964A (en) Bromodomain inhibitors.
IN2014DN09434A (en)
MX2015012850A (en) Arginine methyltransferase inhibitors and uses thereof.
MX2015016425A (en) Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease.
MX2015010829A (en) Therapeutic compounds and uses thereof.
MX2016003823A (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma.
MX2016002580A (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases.
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
PH12017500089B1 (en) Aldosterone synthase inhibitors
MX2013002956A (en) Arylosulfonamides for the treatment of cns diseases.
MX2016006667A (en) Pyrrolopyrrolone derivatives and their use as bet inhibitors.
MX2015007945A (en) Uses and methods for the treatment of liver diseases or conditions.
MX366309B (en) Pharmaceutical composition for treating inflammation and pain.
MY182801A (en) Compound for activating ampk and uses thereof
MX2014014816A (en) Pharmaceutical composition for treating inflammation and pain.
MX2014014817A (en) Compounds for treating inflammation and pain.

Legal Events

Date Code Title Description
FG Grant or registration